Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 23 of 23 entries
Sorted by: Best Match Show Resources per page
Editorial: Levothyroxine Therapy in Patients With Hypothyroidism.

Frontiers in endocrinology

Antonelli A, Wartofsky L, Miccoli P.
PMID: 34354674
Front Endocrinol (Lausanne). 2021 Jul 20;12:734895. doi: 10.3389/fendo.2021.734895. eCollection 2021.

No abstract available.

Cite
Antonelli A, Wartofsky L, Miccoli P. Editorial: Levothyroxine Therapy in Patients With Hypothyroidism. Front Endocrinol (Lausanne). 2021;12:734895doi: 10.3389/fendo.2021.734895.
Antonelli, A., Wartofsky, L., & Miccoli, P. (2021). Editorial: Levothyroxine Therapy in Patients With Hypothyroidism. Frontiers in endocrinology, 12734895. https://doi.org/10.3389/fendo.2021.734895
Antonelli, Alessandro, et al. "Editorial: Levothyroxine Therapy in Patients With Hypothyroidism." Frontiers in endocrinology vol. 12 (2021): 734895. doi: https://doi.org/10.3389/fendo.2021.734895
Antonelli A, Wartofsky L, Miccoli P. Editorial: Levothyroxine Therapy in Patients With Hypothyroidism. Front Endocrinol (Lausanne). 2021 Jul 20;12:734895. doi: 10.3389/fendo.2021.734895. eCollection 2021. PMID: 34354674; PMCID: PMC8329437.
Copy Download .nbib Format: NLM
Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism?.

Frontiers in endocrinology

Gomes-Lima C, Wartofsky L, Burman K.
PMID: 31920970
Front Endocrinol (Lausanne). 2019 Dec 11;10:856. doi: 10.3389/fendo.2019.00856. eCollection 2019.

No abstract available.

Cite
Gomes-Lima C, Wartofsky L, Burman K. Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism?. Front Endocrinol (Lausanne). 2019;10:856doi: 10.3389/fendo.2019.00856.
Gomes-Lima, C., Wartofsky, L., & Burman, K. (2019). Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism?. Frontiers in endocrinology, 10856. https://doi.org/10.3389/fendo.2019.00856
Gomes-Lima, Cristiane, et al. "Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism?." Frontiers in endocrinology vol. 10 (2019): 856. doi: https://doi.org/10.3389/fendo.2019.00856
Gomes-Lima C, Wartofsky L, Burman K. Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism?. Front Endocrinol (Lausanne). 2019 Dec 11;10:856. doi: 10.3389/fendo.2019.00856. eCollection 2019. PMID: 31920970; PMCID: PMC6917573.
Copy Download .nbib Format: NLM
Cytochrome C Oxidase Subunit 4 (COX4): A Potential Therapeutic Target for the Treatment of Medullary Thyroid Cancer.

Cancers

Bikas A, Jensen K, Patel A, Costello J, Reynolds SM, Mendonca-Torres MC, Thakur S, Klubo-Gwiezdzinska J, Ylli D, Wartofsky L, Burman K, Vasko V.
PMID: 32911610
Cancers (Basel). 2020 Sep 08;12(9). doi: 10.3390/cancers12092548.

The nuclear-encoded subunit 4 of cytochrome c oxidase (COX4) plays a role in regulation of oxidative phosphorylation and contributes to cancer progression. We sought to determine the role of COX4 in differentiated (DTC) and medullary (MTC) thyroid cancers. We...

Cite
Bikas A, Jensen K, Patel A, et al. Cytochrome C Oxidase Subunit 4 (COX4): A Potential Therapeutic Target for the Treatment of Medullary Thyroid Cancer. Cancers (Basel). 2020;12(9)doi: 10.3390/cancers12092548.
Bikas, A., Jensen, K., Patel, A., Costello, J., Reynolds, S. M., Mendonca-Torres, M. C., Thakur, S., Klubo-Gwiezdzinska, J., Ylli, D., Wartofsky, L., Burman, K., & Vasko, V. (2020). Cytochrome C Oxidase Subunit 4 (COX4): A Potential Therapeutic Target for the Treatment of Medullary Thyroid Cancer. Cancers, 12(9), . https://doi.org/10.3390/cancers12092548
Bikas, Athanasios, et al. "Cytochrome C Oxidase Subunit 4 (COX4): A Potential Therapeutic Target for the Treatment of Medullary Thyroid Cancer." Cancers vol. 12,9 (2020). doi: https://doi.org/10.3390/cancers12092548
Bikas A, Jensen K, Patel A, Costello J, Reynolds SM, Mendonca-Torres MC, Thakur S, Klubo-Gwiezdzinska J, Ylli D, Wartofsky L, Burman K, Vasko V. Cytochrome C Oxidase Subunit 4 (COX4): A Potential Therapeutic Target for the Treatment of Medullary Thyroid Cancer. Cancers (Basel). 2020 Sep 08;12(9). doi: 10.3390/cancers12092548. PMID: 32911610; PMCID: PMC7565757.
Copy Download .nbib Format: NLM
Statement of principle.

Hormones & cancer

Cefalu WT, Nair KS, Seaquist ER, Zierath J, Boulton AJ, LeRoith D, Harrell RM, Grunberger G, Wartofsky L, Gore AC, Wierman ME, Hammes SR, Lange CA, Santen RJ.
PMID: 25410830
Horm Cancer. 2015 Feb;6(1):1. doi: 10.1007/s12672-014-0206-x.

No abstract available.

Cite
Cefalu WT, Nair KS, Seaquist ER, et al. Statement of principle. Horm Cancer. 2015;6(1):1doi: 10.1007/s12672-014-0206-x.
Cefalu, W. T., Nair, K. S., Seaquist, E. R., Zierath, J., Boulton, A. J., LeRoith, D., Harrell, R. M., Grunberger, G., Wartofsky, L., Gore, A. C., Wierman, M. E., Hammes, S. R., Lange, C. A., & Santen, R. J. (2015). Statement of principle. Hormones & cancer, 6(1), 1. https://doi.org/10.1007/s12672-014-0206-x
Cefalu, William T, et al. "Statement of principle." Hormones & cancer vol. 6,1 (2015): 1. doi: https://doi.org/10.1007/s12672-014-0206-x
Cefalu WT, Nair KS, Seaquist ER, Zierath J, Boulton AJ, LeRoith D, Harrell RM, Grunberger G, Wartofsky L, Gore AC, Wierman ME, Hammes SR, Lange CA, Santen RJ. Statement of principle. Horm Cancer. 2015 Feb;6(1):1. doi: 10.1007/s12672-014-0206-x. PMID: 25410830.
Copy Download .nbib Format: NLM
Bone metastasis from noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); a case report.

BMC endocrine disorders

Fakhar Y, Khooei A, Aghaee A, Mohammadzadeh Kosari H, Wartofsky L, Zakavi SR.
PMID: 34736430
BMC Endocr Disord. 2021 Nov 04;21(1):221. doi: 10.1186/s12902-021-00883-7.

BACKGROUND: The term non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) was recently proposed as a non-malignant thyroid lesion with indolent behavior that does not require post-operative radio-iodine treatment. We are reporting a case of NIFTP with bone...

Cite
Fakhar Y, Khooei A, Aghaee A, et al. Bone metastasis from noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); a case report. BMC Endocr Disord. 2021;21(1):221doi: 10.1186/s12902-021-00883-7.
Fakhar, Y., Khooei, A., Aghaee, A., Mohammadzadeh Kosari, H., Wartofsky, L., & Zakavi, S. R. (2021). Bone metastasis from noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); a case report. BMC endocrine disorders, 21(1), 221. https://doi.org/10.1186/s12902-021-00883-7
Fakhar, Yasaman, et al. "Bone metastasis from noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); a case report." BMC endocrine disorders vol. 21,1 (2021): 221. doi: https://doi.org/10.1186/s12902-021-00883-7
Fakhar Y, Khooei A, Aghaee A, Mohammadzadeh Kosari H, Wartofsky L, Zakavi SR. Bone metastasis from noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP); a case report. BMC Endocr Disord. 2021 Nov 04;21(1):221. doi: 10.1186/s12902-021-00883-7. PMID: 34736430; PMCID: PMC8567706.
Copy Download .nbib Format: NLM
30 mCi exploratory scan for two-step dosimetric .

World journal of nuclear medicine

Wu D, Gomes-Lima CJ, Kulkarni K, Burman KD, Wartofsky L, Van Nostrand D.
PMID: 33354183
World J Nucl Med. 2020 Jan 17;19(3):266-270. doi: 10.4103/wjnm.WJNM_35_19. eCollection 2020.

Differentiated thyroid cancer patients with significantly elevated or rapidly rising serum thyroglobulin (Tg) levels and negative diagnostic radioiodine scans (DxScan) often present a therapeutic dilemma in deciding whether or not to administer an

Cite
Wu D, Gomes-Lima CJ, Kulkarni K, et al. 30 mCi exploratory scan for two-step dosimetric . World J Nucl Med. 2020;19(3):266-270doi: 10.4103/wjnm.WJNM_35_19.
Wu, D., Gomes-Lima, C. J., Kulkarni, K., Burman, K. D., Wartofsky, L., & Van Nostrand, D. (2020). 30 mCi exploratory scan for two-step dosimetric . World journal of nuclear medicine, 19(3), 266-270. https://doi.org/10.4103/wjnm.WJNM_35_19
Wu, Di, et al. "30 mCi exploratory scan for two-step dosimetric ." World journal of nuclear medicine vol. 19,3 (2020): 266-270. doi: https://doi.org/10.4103/wjnm.WJNM_35_19
Wu D, Gomes-Lima CJ, Kulkarni K, Burman KD, Wartofsky L, Van Nostrand D. 30 mCi exploratory scan for two-step dosimetric . World J Nucl Med. 2020 Jan 17;19(3):266-270. doi: 10.4103/wjnm.WJNM_35_19. eCollection 2020. PMID: 33354183; PMCID: PMC7745862.
Copy Download .nbib Format: NLM
Screening for thyroid disease: defining high-risk populations.

Expert review of endocrinology & metabolism

Stein SA, Wartofsky L.
PMID: 30764020
Expert Rev Endocrinol Metab. 2010 Sep;5(5):663-671. doi: 10.1586/eem.10.34.

The pros and cons of population screening for thyroid disease have been hotly debated over the past several decades. This article addresses the issue from the point of view of the potential benefit of screening, that is, disease detection....

Cite
Stein SA, Wartofsky L. Screening for thyroid disease: defining high-risk populations. Expert Rev Endocrinol Metab. 2010;5(5):663-671doi: 10.1586/eem.10.34.
Stein, S. A., & Wartofsky, L. (2010). Screening for thyroid disease: defining high-risk populations. Expert review of endocrinology & metabolism, 5(5), 663-671. https://doi.org/10.1586/eem.10.34
Stein, Stephanie Aleskow, and Wartofsky, Leonard. "Screening for thyroid disease: defining high-risk populations." Expert review of endocrinology & metabolism vol. 5,5 (2010): 663-671. doi: https://doi.org/10.1586/eem.10.34
Stein SA, Wartofsky L. Screening for thyroid disease: defining high-risk populations. Expert Rev Endocrinol Metab. 2010 Sep;5(5):663-671. doi: 10.1586/eem.10.34. PMID: 30764020.
Copy Download .nbib Format: NLM
Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine.

European endocrinology

Baxi SS, Kurtzman R, Eaton A, Dewey E, Bickford C, Fish S, Wartofsky L, Michael Tuttle R.
PMID: 29632603
Eur Endocrinol. 2017 Apr;13(1):26-29. doi: 10.17925/EE.2017.13.01.26. Epub 2017 Apr 03.

No abstract available.

Cite
Baxi SS, Kurtzman R, Eaton A, et al. Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine. Eur Endocrinol. 2017;13(1):26-29doi: 10.17925/EE.2017.13.01.26.
Baxi, S. S., Kurtzman, R., Eaton, A., Dewey, E., Bickford, C., Fish, S., Wartofsky, L., & Michael Tuttle, R. (2017). Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine. European endocrinology, 13(1), 26-29. https://doi.org/10.17925/EE.2017.13.01.26
Baxi, Shrujal S, et al. "Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine." European endocrinology vol. 13,1 (2017): 26-29. doi: https://doi.org/10.17925/EE.2017.13.01.26
Baxi SS, Kurtzman R, Eaton A, Dewey E, Bickford C, Fish S, Wartofsky L, Michael Tuttle R. Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine. Eur Endocrinol. 2017 Apr;13(1):26-29. doi: 10.17925/EE.2017.13.01.26. Epub 2017 Apr 03. PMID: 29632603; PMCID: PMC5813442.
Copy Download .nbib Format: NLM
Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulin.

Thyroid : official journal of the American Thyroid Association

Ylli D, Soldin SJ, Stolze B, Wei B, Nigussie G, Nguyen H, Mendu DR, Mete M, Wu D, Gomes-Lima CJ, Klubo-Gwiezdzinska J, Burman KD, Wartofsky L.
PMID: 34042535
Thyroid. 2021 Aug;31(8):1160-1170. doi: 10.1089/thy.2020.0866. Epub 2021 May 26.

No abstract available.

Cite
Ylli D, Soldin SJ, Stolze B, et al. Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulin. Thyroid. 2021;31(8):1160-1170doi: 10.1089/thy.2020.0866.
Ylli, D., Soldin, S. J., Stolze, B., Wei, B., Nigussie, G., Nguyen, H., Mendu, D. R., Mete, M., Wu, D., Gomes-Lima, C. J., Klubo-Gwiezdzinska, J., Burman, K. D., & Wartofsky, L. (2021). Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulin. Thyroid : official journal of the American Thyroid Association, 31(8), 1160-1170. https://doi.org/10.1089/thy.2020.0866
Ylli, Dorina, et al. "Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulin." Thyroid : official journal of the American Thyroid Association vol. 31,8 (2021): 1160-1170. doi: https://doi.org/10.1089/thy.2020.0866
Ylli D, Soldin SJ, Stolze B, Wei B, Nigussie G, Nguyen H, Mendu DR, Mete M, Wu D, Gomes-Lima CJ, Klubo-Gwiezdzinska J, Burman KD, Wartofsky L. Biotin Interference in Assays for Thyroid Hormones, Thyrotropin and Thyroglobulin. Thyroid. 2021 Aug;31(8):1160-1170. doi: 10.1089/thy.2020.0866. Epub 2021 May 26. PMID: 34042535; PMCID: PMC8420951.
Copy Download .nbib Format: NLM
Editorial: Levothyroxine Therapy in Patients With Hypothyroidism.

Frontiers in endocrinology

Antonelli A, Wartofsky L, Miccoli P.
PMID: 34354674
Front Endocrinol (Lausanne). 2021 Jul 20;12:734895. doi: 10.3389/fendo.2021.734895. eCollection 2021.

No abstract available.

Cite
Antonelli A, Wartofsky L, Miccoli P. Editorial: Levothyroxine Therapy in Patients With Hypothyroidism. Front Endocrinol (Lausanne). 2021;12:734895doi: 10.3389/fendo.2021.734895.
Antonelli, A., Wartofsky, L., & Miccoli, P. (2021). Editorial: Levothyroxine Therapy in Patients With Hypothyroidism. Frontiers in endocrinology, 12734895. https://doi.org/10.3389/fendo.2021.734895
Antonelli, Alessandro, et al. "Editorial: Levothyroxine Therapy in Patients With Hypothyroidism." Frontiers in endocrinology vol. 12 (2021): 734895. doi: https://doi.org/10.3389/fendo.2021.734895
Antonelli A, Wartofsky L, Miccoli P. Editorial: Levothyroxine Therapy in Patients With Hypothyroidism. Front Endocrinol (Lausanne). 2021 Jul 20;12:734895. doi: 10.3389/fendo.2021.734895. eCollection 2021. PMID: 34354674; PMCID: PMC8329437.
Copy Download .nbib Format: NLM
Do Molecular Profiles of Primary .

Frontiers in endocrinology

Gomes-Lima CJ, Shobab L, Wu D, Ylli D, Bikas A, McCoy M, Feldman R, Lee W, Rao SN, Jensen K, Vasko V, Castro LC, Jonklaas J, Wartofsky L, Burman KD.
PMID: 33716974
Front Endocrinol (Lausanne). 2021 Feb 25;12:623182. doi: 10.3389/fendo.2021.623182. eCollection 2021.

Management of metastatic radioiodine refractory differentiated thyroid cancer (DTC) can be a therapeutic challenge. Generally, little is known about the paired molecular profile of the primary tumor and the metastases and whether they harbor the same genetic abnormalities. The...

Cite
Gomes-Lima CJ, Shobab L, Wu D, et al. Do Molecular Profiles of Primary . Front Endocrinol (Lausanne). 2021;12:623182doi: 10.3389/fendo.2021.623182.
Gomes-Lima, C. J., Shobab, L., Wu, D., Ylli, D., Bikas, A., McCoy, M., Feldman, R., Lee, W., Rao, S. N., Jensen, K., Vasko, V., Castro, L. C., Jonklaas, J., Wartofsky, L., & Burman, K. D. (2021). Do Molecular Profiles of Primary . Frontiers in endocrinology, 12623182. https://doi.org/10.3389/fendo.2021.623182
Gomes-Lima, Cristiane J, et al. "Do Molecular Profiles of Primary ." Frontiers in endocrinology vol. 12 (2021): 623182. doi: https://doi.org/10.3389/fendo.2021.623182
Gomes-Lima CJ, Shobab L, Wu D, Ylli D, Bikas A, McCoy M, Feldman R, Lee W, Rao SN, Jensen K, Vasko V, Castro LC, Jonklaas J, Wartofsky L, Burman KD. Do Molecular Profiles of Primary . Front Endocrinol (Lausanne). 2021 Feb 25;12:623182. doi: 10.3389/fendo.2021.623182. eCollection 2021. PMID: 33716974; PMCID: PMC7949910.
Copy Download .nbib Format: NLM
Showing 13 to 23 of 23 entries